Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
7.30
+0.45 (6.57%)
Mar 9, 2026, 1:51 PM EDT - Market open
Lexeo Therapeutics Employees
Lexeo Therapeutics had 72 employees as of December 31, 2024. The number of employees increased by 14 or 24.14% compared to the previous year.
Employees
72
Change (1Y)
14
Growth (1Y)
24.14%
Revenue / Employee
n/a
Profits / Employee
-$1,720,754
Market Cap
532.81M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 72 | 14 | 24.14% |
| Dec 31, 2023 | 58 | 34 | 141.67% |
| Dec 31, 2021 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MeiraGTx Holdings | 409 |
| REGENXBIO | 371 |
| Allogene Therapeutics | 229 |
| Alpha Tau Medical | 125 |
| Solid Biosciences | 100 |
| Ocugen | 95 |
| Neumora Therapeutics | 95 |
| Verastem | 78 |
LXEO News
- 6 days ago - Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - GlobeNewsWire
- 23 days ago - Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 4 weeks ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - GlobeNewsWire
- 5 weeks ago - Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics - GlobeNewsWire
- 7 weeks ago - Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript - Seeking Alpha
- 2 months ago - Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire